Taming of the Shrew Spit
Soricimed, Moncton, New Brunswick Jenny Keleher March 31, 2016
Ce contenu est seulement disponible en anglais
Click here to read the story at Biotech.ca.
Originally thought to be a treatment for pain relief further research has opened up even more capabilities including cancer-fighting potential. The treatment works by targeting a calcium channel that exists only in cancer cells. Calcium fuels the growth of the cancerous cell. By capping the channel, Soricimed’s drug cuts off the calcium supply and, ultimately, helps kill the cell. And because normal cells lack the calcium channel, they are left unaffected. The company has also developed a blood test that detects early-stage cancers by identifying the presence of the calcium channel.
Soricimed Granted Orphan Designation from US FDA for treatment of Ovarian Cancer(March 2016)